CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
ixabepilonedrug
Likely dose
Ixabepilone given intravenouslyAI-extracted
Key inclusion· 6
  • ✓Histologically confirmed aggressive non-Hodgkin's lymphoma: Grade III follicular, DLBCL, mantle cell, primary mediastinal B-cell, Burkitt, high-grade B-cell (Burkitt-like), or CD30+ anaplastic large cell lymphoma
  • ✓Relapsed or refractory disease after prior standard chemotherapy: either CR/PR lasting ≥4 weeks after most recent prior therapy (chemosensitive), or stable disease/PR but no progressive disease (refractory)
  • ✓At least one bidimensionally measurable lesion ≥10 mm by conventional imaging or clinical exam
  • ✓ECOG performance status 0-2
Key exclusion· 6
  • ✕Known CNS involvement by lymphoma (except prior successfully treated disease with relapse exclusively outside CNS)
  • ✕Prior allergic reaction or hypersensitivity to Cremophor EL or compounds of similar chemical or biological composition to BMS-247550
  • ✕Peripheral neuropathy grade 2 or greater
  • ✕Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00058019
NCT00058019Phase 2Completed
CompareCT.gov

A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas

National Cancer Institute (NCI)·interventional·Posted Apr 9, 2003·Updated May 23, 2014

In Brief

A Phase 2 clinical trial evaluating ixabepilone for Anaplastic Large Cell Lymphoma and 5 related conditions. Completed, enrolled 51 participants across 2 sites.

Detailed Summary

This phase II trial is studying how well ixabepilone works in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop cancer cells from dividing so they stop growing or die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 9, 2003
Enrollment StartFeb 1, 2003
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 23.2 years ago

Interventions

ixabepilonedrug

Given IV